Therefore, this review primarily focuses on the correlation between purines/purinergic receptors and tumors, with particular emphasis on the pivotal role played by the receptor P2X7R in tumor progression, immunotherapy characteristics, and prospects for clinical application. This evidence concerns the gene P2RY1 and neoplasm.